LRRC15

Across TCGA pan-cancer cohorts, LRRC15 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LRRC15 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LRRC15 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LRRC15 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, LSCC, and GBM are the cancer types where LRRC15 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.588	0.842	.003	54	view →
LSCC	DFS	Median	All	0.550	0.843	<.001	32	view →
GBM	DFS	Median	All	0.187	0.583	<.001	17	view →
LUAD	DFS	Tertile	All	0.976	0.832	.013	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LRRC15–PDAC (DFS)

Open the PDAC breakdown →